Susanna Varkey Ulahannan

Susanna Varkey Ulahannan

Auto-generated profile, based on publicly available information

Susanna Varkey Ulahannan

Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
ADAustin G. Duffy
Austin G. Duffy
SUSusanna V. Ulahannan
Susanna V. Ulahannan
OMOxana Makorova-Rusher
Oxana Makorova-Rusher
OROsama Rahma
Osama Rahma
HWHeiner Wedemeyer
Heiner Wedemeyer
TGTim F. Greten
Tim F. Greten

21 March 2016 in Cancer
Verified
Journal Article
Open access
PDF file
OMOxana V. Makarova‐Rusher
Oxana V. Makarova‐Rusher
SASean F. Altekruse
Sean F. Altekruse
TMTim S. McNeel
Tim S. McNeel
SUSusanna Ulahannan
Susanna Ulahannan
ADAustin G. Duffy
Austin G. Duffy
KMKatherine McGlynn
Katherine McGlynn
BACKGROUND: Hepatocellular carcinoma (HCC) incidence has been increasing in the United States for several decades; and, as the incidence of hepatitis C virus (HCV) infection declines and the prevalence of metabolic disorders rises, the proportion of HCC attributable to various risk factors may be changing.METHODS: Data from the Surveillance, Epidemiology, and End Results‐Medicare linkage were used to calculate population attributable fractions (PAFs) for each risk factor over time. Patients with HCC (n = 10,708) who were diagnosed during the years 2000 through 2011 were compared with a 5% random sample of cancer‐free controls (n = 332,107) residing in the Surveillance, Epidemiology, and End Results areas. Adjusted odds ratios (ORs) and PAFs were calculated for HCV, hepatitis B virus (HBV), metabolic disorders, alcohol‐related disorders, smoking, and genetic disorders.RESULTS: Overall, the PAF was greatest for metabolic disorders (32%), followed by HCV (20.5%), alcohol (13.4%), smoking (9%), HBV (4.3%), and genetic disorders (1.5%). The PAF for all factors combined was 59.5%. PAFs differed by race/ethnicity and sex. Metabolic disorders had the largest PAF among Hispanics (PAF, 39.3%; 95% confidence interval [CI], 31.9%‐46.7%) and whites (PAF, 34.8%; 95% CI, 33.1%‐36.5%), whereas HCV had the largest PAF among blacks (PAF, 36.1%; 95% CI, 31.8%‐40.4%) and Asians (PAF, 29.7%; 95% CI, 25.9%‐33.4%). Between 2000 and 2011, the PAF of metabolic disorders increased from 25.8% (95% CI, 22.8%‐28.9%) to 36% (95% CI, 33.6%‐38.5%). In contrast, the PAFs of alcohol‐related disorders and HCV remained stable.CONCLUSIONS: Among US Medicare recipients, metabolic disorders contribute more to the burden of HCC than any other risk factor, and the fraction of HCC caused by metabolic disorders has increased in the last decade. Cancer 2016;122:1757‐65. Published 2016. This article is a U.S. Government work and is in the public domain in the USA..

1 March 2024 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
DMDivya Murthy
Divya Murthy
KAKuldeep S. Attri
Kuldeep S. Attri
SSSurendra K. Shukla
Surendra K. Shukla
RAVI THAKURRAVI THAKUR
RAVI THAKUR
NCNina V. Chaika
Nina V. Chaika
PSPankaj Singh
Pankaj Singh
The ability of tumour cells to thrive in harsh microenvironments depends on the utilization of nutrients available in the milieu. Here we show that pancreatic cancer-associated fibroblasts (CAFs) regulate tumour cell metabolism through the secretion of acetate, which can be blocked by silencing ATP citrate lyase (ACLY) in CAFs. We further show that acetyl-CoA synthetase short-chain family member 2 (ACSS2) channels the exogenous acetate to regulate the dynamic cancer epigenome and transcriptome, thereby facilitating cancer cell survival in an acidic microenvironment. Comparative H3K27ac ChIP–seq and RNA–seq analyses revealed alterations in polyamine homeostasis through regulation of SAT1 gene expression and enrichment of the SP1-responsive signature. We identified acetate/ACSS2-mediated acetylation of SP1 at the lysine 19 residue that increased SP1 protein stability and transcriptional activity. Genetic or pharmacologic inhibition of the ACSS2–SP1–SAT1 axis diminished the tumour burden in mouse models. These results reveal that the metabolic flexibility imparted by the stroma-derived acetate enabled cancer cell survival under acidosis via the ACSS2–SP1–SAT1 axis.

31 August 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ELEmerson A. Lim
Emerson A. Lim
JBJohanna C. Bendell
Johanna C. Bendell
GFGerald S. Falchook
Gerald S. Falchook
TBTodd M. Bauer
Todd M. Bauer
CDCharles G. Drake
Charles G. Drake
MPManish R. Patel
Manish R. Patel
Purpose: To evaluate AZD4635, an adenosine A2A receptor antagonist, as monotherapy or in combination with durvalumab in patients with advanced solid tumors. Patients and Methods: In phase Ia (dose escalation), patients had relapsed/refractory solid tumors; in phase Ib (dose expansion), patients had checkpoint inhibitor–naïve metastatic castration-resistant prostate cancer (mCRPC) or colorectal carcinoma, non–small cell lung cancer with prior anti–PD-1/PD-L1 exposure, or other solid tumors (checkpoint-naïve or prior anti–PD-1/PD-L1 exposure). Patients received AZD4635 monotherapy (75–200 mg once daily or 125 mg twice daily) or in combination with durvalumab (AZD4635 75 or 100 mg once daily). The primary objective was safety; secondary objectives included antitumor activity and pharmacokinetics; exploratory objectives included evaluation of an adenosine gene signature in patients with mCRPC. Results: As of September 8, 2020, 250 patients were treated (AZD4635, n = 161; AZD4635+durvalumab, n = 89). In phase Ia, DLTs were observed with monotherapy (125 mg twice daily; n = 2) and with combination treatment (75 mg; n = 1) in patients receiving nanosuspension. The most common treatment-related adverse events included nausea, fatigue, vomiting, decreased appetite, dizziness, and diarrhea. The RP2D of the AZD4635 capsule formulation was 75 mg once daily, as monotherapy or in combination with durvalumab. The pharmacokinetic profile was dose-proportional, and exposure was adequate to cover target with 100 mg nanosuspension or 75 mg capsule once daily. In patients with mCRPC receiving monotherapy or combination treatment, tumor responses (2/39 and 6/37, respectively) and prostate-specific antigen responses (3/60 and 10/45, respectively) were observed. High versus low blood-based adenosine signature was associated with median progression-free survival of 21 weeks versus 8.7 weeks. Conclusions: AZD4635 monotherapy or combination therapy was well tolerated. Objective responses support additional phase II combination studies in patients with mCRPC.

19 May 2016 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
ADA.G. Duffy
A.G. Duffy
OMO.V. Makarova‐Rusher
O.V. Makarova‐Rusher
SUS.V. Ulahannan
S.V. Ulahannan
ORO.E. Rahma
O.E. Rahma
SFS. Fioravanti
S. Fioravanti
TGTim F. Greten
Tim F. Greten
The eukaryotic translation initiation factor 4E (eIF4E) is a potent oncogene that is found to be dysregulated in 30% of human cancer, including colorectal carcinogenesis (CRC). ISIS 183750 is a second‐generation antisense oligonucleotide (ASO) designed to inhibit the production of the eIF4E protein. In preclinical studies we found that EIF4e ASOs reduced expression of EIF4e mRNA and inhibited proliferation of colorectal carcinoma cells. An additive antiproliferative effect was observed in combination with irinotecan. We then performed a clinical trial evaluating this combination in patients with refractory cancer. No dose‐limiting toxicities were seen but based on pharmacokinetic data and tolerability the dose of irinotecan was reduced to 160 mg/m2 biweekly. Efficacy was evaluated in 15 patients with irinotecan‐refractory colorectal cancer. The median time of disease control was 22.1 weeks. After ISIS 183750 treatment, peripheral blood levels of eIF4E mRNA were decreased in 13 of 19 patients. Matched pre‐ and posttreatment tumor biopsies showed decreased eIF4E mRNA levels in five of nine patients. In tumor tissue, the intracellular and stromal presence of ISIS 183750 was detected by IHC in all biopsied patients. Although there were no objective responses stable disease was seen in seven of 15 (47%) patients who were progressing before study entry, six of whom were stable at the time of the week 16 CT scan. We were also able to confirm through mandatory pre‐ and posttherapy tumor biopsies penetration of the ASO into the site of metastasis.

4 July 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
SUSusanna V. Ulahannan
Susanna V. Ulahannan
ADAustin G. Duffy
Austin G. Duffy
TMTimothy S. McNeel
Timothy S. McNeel
JKJonathan K. Kish
Jonathan K. Kish
LDLois A. Dickie
Lois A. Dickie
SASean F. Altekruse
Sean F. Altekruse
The purpose of the study was to assess the use of curative therapies for hepatocellular carcinoma (HCC) in the population. HCC treatment patterns were examined in Surveillance, Epidemiology, and End Results (SEER) 18 registries (28% of U.S.). Joinpoint regression analyses were performed to assess 2000-2010 incidence trends by tumor size, count, and receipt of potentially curative treatments (transplantation, resection, and ablation). SEER-Medicare data enabled evaluation of treatment patterns including receipt of sorafenib or transarterial chemoembolization (TACE) by HCC-associated comorbidities. Diagnoses of tumors ≤5.0 cm in diameter significantly increased during 2000-2010, surpassing diagnosis of larger tumors. Overall, 23% of cases received potentially curative treatment. Joinpoint models indicated incidence rates of treatment with curative intent increased 17.6% per year during 2000-2005, then declined by −2.9% per year during 2005-2010 ( P < 0.001). Among HCC cases with a single tumor ≤5.0 cm and no extension beyond the liver, use of ablative therapy significantly increased during 2000-2010. Use of invasive surgery for single tumors, regardless of size, significantly increased during the initial years of the decade, then plateaued. The group most likely to receive curative treatment in the SEER-Medicare cases was patients with one, small tumor confined to the liver (657 of 1,597 cases, 41%), with no difference in treatment by hepatic comorbidity status ( P = 0.24). A higher proportion of cases with reported liver-associated comorbidities were, however, diagnosed with tumors ≤5.0 cm in diameter (1,745 0f 2,464, 71%) compared to patients with no reported comorbidities (996 of 2,596, 38%, P < 0.001). Conclusion : Although more HCC patients were diagnosed with early disease over time, the use of curative treatments in this patient group has recently plateaued. Efforts to identify and treat more eligible candidates for curative therapy could be beneficial. (Hepatology 2014;60:1637–1644)